WinVest Acquisition Corp. Announces Extension of Termination Date and Additional Contribution to Trust Account to Extend Termination Date

(Other OTC:WINV),(OTC US:WINV), Cambridge, MA, Aug. 14, 2025 (GLOBE NEWSWIRE) — WinVest Acquisition Corp. (OTC: WINV, the “Company”), a special purpose acquisition company, announced today that its Board of Directors (the “Board”) has approved an extension of the period of time available to the Company to consummate an initial business combination by one month from […]

Jefferson Capital Reports Second Quarter 2025 Results

(NASDAQ:JCAP), 47% Growth in Revenue to $152.7 MillionCollections Grow 85% to $255.7 Million with Estimated Remaining Collections (“ERC”) up 31% to a Record $2.9 BillionPre-tax Income up 82% to $62.0 Million with Net Income up 48% to $47.7 MillionAdjusted Pre-tax Income up 55% to $61.7 MillionBoard of Directors Declares Quarterly Cash Dividend of $0.24 per

zSpace Reports Second Quarter 2025 Financial Results

(NasdaqGM:ZSPC), SAN JOSE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — zSpace (NASDAQ: ZSPC) (“zSpace” or the “Company”), a leader in augmented and virtual reality solutions for education, is announcing its financial results for the three and six months ended June 30, 2025. “We are pleased with the strategic and operational progress we made in the

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

(NASDAQ:ANNX), Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA Accelerated Completion of Enrollment for Global Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry AMD with GA; Selected for EMA PRIME

Unitil Announces Common Stock Offering

(NYSE:UTL), HAMPTON, N.H., Aug. 14, 2025 (GLOBE NEWSWIRE) — Unitil Corporation (NYSE: UTL) (unitil.com) (the “Company”) today announced a registered offering of $65,000,000 of shares of its common stock. The Company's common stock is listed on the New York Stock Exchange under the symbol “UTL.” The Company has granted the underwriters of the offering an

Innventure Reports Second Quarter 2025 Results

(NasdaqGM:INV),(NASDAQ:INVW), Accelsius significantly grew market presence with recent deployments at Global Switch, Compucenter and Equinix facilities AeroFlexx delivered a fourth consecutive quarter of revenue generation Refinity engaged an engineering, procurement and construction partner for the first plant design ORLANDO, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) — Innventure, Inc. (NASDAQ: INV) (“Innventure”), a technology commercialization platform,

Intchains Group Limited Reports Second Quarter and First Half 2025 Financial Results

(NASDAQ:ICG), Reinforces its Leading ETH Treasury Position: Increased ETH holdings to 8,816 as of June 30, 2025, up 26% from March 31, 2025, and 55% from December 31, 2024 Updates on Its Long-Term Dollar-Cost Averaging ETH Treasury Strategy Designed to Boost Overall Yield Performance SINGAPORE, Aug. 14, 2025 (GLOBE NEWSWIRE) — Intchains Group Limited (Nasdaq:

NANO Nuclear Reports Third Fiscal Quarter 2025 Financial Results and Provides Business Update

(NASDAQ:NNE), New York, N.Y., Aug. 14, 2025 (GLOBE NEWSWIRE) — NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today reported its third fiscal quarter financial results and provided a business update. “NANO Nuclear continues to benefit from a

CapsoVision Reports Second Quarter 2025 Financial Results

(NASDAQ:CV), SARATOGA, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its second quarter ended June 30, 2025. Recent Highlights Second quarter 2025 revenue was $3.3 million, a 17% increase over the second quarter of

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

(NASDAQ:FBIO),(NASDAQ:FBIOP), Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on future net sales of UNLOXCYT(TM) (cosibelimab-ipdl) FDA accepted New Drug Application filing for priority review of CUTX-101 to

Scroll to Top